Larimar Therapeutics Inc (LRMR)
Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for rare diseases through its cell-penetrating peptide platform. Its lead candidate, CTI-1601, is being evaluated in a Phase 2 open-label extension study for Friedreich’s ataxia, a rare, progressive, and fatal disease. The company is headquartered in Bala Cynwyd, Pennsylvania, and its common stock trades on the NASDAQ under the ticker LRMR.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LRMR
|
$4.53
|
18.6% Upside
|
Undervalued
|
$14.40
|
277.0% Upside
|
Bargain
|
Weak
|
0.0%
|
November 5, 2026
|
3.1x
|
398.7 M
|
247.4 M
|
1.2%
|
55.5%
|
-0.5
|
90.4%
|
